San Diego, CA - The research community has been seriously challenged in recent years with reports of a “Reproducibility Crisis” that has threatened the public’s confidence in published data coming out of peer reviewed journals. It was estimated in 2015 that the economic costs associated with irreproducible research are approximately $28B in the USA alone.
Further analysis has estimated that nearly one third of the total monetary loss (~$10B) is due to the research products that are used in the experiments. While many have pointed to a lack of traceability of the reagents as a major reason for their culpability, there is now a growing concern of counterfeit research products infiltrating the research marketplace.
Richmond, CA - One of the most promising areas in the new, ground-breaking field of synthetic biology is known as immunotherapy. Immunotherapy has been receiving praise for the development of Chimeric Antigen Receptor (CAR) T-cells.
The success of immunotherapy is now undeniable; two therapeutics from Novartis and Gilead/Kite Pharma have been approved by the FDA to treat various blood cancers. This is the first time ever the FDA has approved a genetically modified based cell therapy.
However, the same treatment that produced miraculous results can also subject its recipients to negative side effects: flu-like symptoms which can potentially be coma-inducing… and even fatal.
ProMab Biotechnologies (PMB) has discovered how to genetically engineer out the most harmful side-effect of the therapy, called Cytokine Release Syndrome (CRS) which is associated with CAR-T-cells. The significant reduction in CRS will not only save lives, but will help make the life-saving treatment more accessible.